BCNA’s Annual Review 2020-21 now available
Our latest Annual Review for 2020–21 is now available. Tracking the first 18 months of the pandemic to BCNA’s new June financial year-end, it reflects the strength and determination of our network to meet the challenges of the times.
During this time, BCNA pivoted to respond to the critical needs of our network, seamlessly delivering information and support and raising our collective voice to address disruptions in the health sector that affected those diagnosed with breast cancer.
Thanks to our engaged network, committed partners and dedicated staff, BCNA continues to be a vital influencer and change-maker.
BCNA submissions to PBAC
As part of BCNA’s commitment to reduce the financial burden of breast cancer, we regularly make submissions on behalf of our members to the Pharmaceutical Benefits Advisory Committee in support of new breast cancer treatments. The PBAC is the authority that makes recommendations to the Australian Government on which drugs should be subsidised through the Pharmaceutical Benefits Schedule (PBS).
In the last three months, BCNA has made submissions in strong support of two breast cancer treatments being included on the PBS:
Access programs are being run for both treatments, and BCNA recommends speaking directly to your oncologist or treating team if you have questions regarding these treatments or your eligibility to access them.
We are expecting the outcomes of these submissions over the coming months, and will keep our network informed and up-to-date on all available and emerging treatments. BCNA thanks the consumers who offered their insight into these submissions and are helping us to advocate for affordable breast cancer treatments in Australia.